Outcomes
anaemia, haemoglobinuria, vomiting
ADVERSE EVENTS, EVENT, ANAEMIA
The primary endpoint was the incidence risk of There were multiple safety outcomes. First the proportion of patients vomiting their medication on the day of enrolment within 1 h of administration and the proportion of patients vomiting any of their primaquine doses within 1 h of administration. Second, the proportion of adverse events and serious adverse events, as well as the proportion of patients experiencing severe (haemoglobin <5 g/dL) and moderately severe (haemoglobin <7 g/dL) anaemia or the risk for blood transfusion between day 2 and day 7. Finally, the proportion of patients experiencing a 25% or greater reduction in haemoglobin to under 7 g/dL with and without haemoglobinuria at day 2 and day 7, which was defined as a clinically significant event associated with increased mortality.